This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
TUBA1A / Tubulin alpha-1A chain · IHC design guide
Design Immunohistochemistry for TUBA1A
Plan TUBA1A paraffin-section IHC around its general cytoplasmic staining pattern (HPA tissue IHC). Compare high staining in cortical neurons with staining reported as undetected in skeletal myocytes, while accounting for possible recognition of proteins from more than one gene (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
TUBA1A Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | General cytoplasmic tissue staining (HPA tissue IHC) | |
| Staining pattern | High cytoplasmic staining in cortical and caudate neurons (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen) | |
| Positive control | Adrenal gland+4 more · see all | |
| Negative control | Skeletal muscle |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across paraffin sections (standard IHC practice; not target-specific) | |
| Caveat | Staining may reflect protein from more than one gene (HPA tissue IHC) | |
| Regulation | High expression in fetal brain (UniProt) | |
| Isoform / epitope | 2 isoforms; terminal processing may alter epitopes (UniProt) |
Section 1
Recommended TUBA1A IHC & IF Protocols
Compare the catalog antibody’s IHC-P protocol with published tissue-microarray and confocal tissue-section IHC methods (PMC11975906; PMC9818799).
| Sample | Tissue sections; selected-image fixative not specified (standard IHC workflow) |
| Fixation | Image fixative and duration unreported (datasheet A03989); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat-induced epitope retrieval in citrate buffer, pH 6.0, 20 min at 95–98 °C (standard rule: cytoplasmic / membrane antigen) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit anti-TUBA1A, 2.5 μg/mL (datasheet A03989) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | TUBA1A-positive staining in glandular cells of adrenal gland (HPA tissue IHC: High). HPA tissue profile: General cytoplasmic expression. No signal in the no-primary control. |
💡Decision noteStart with citrate pH 6.0 HIER at 95–98 °C for 20 min (page antigen-retrieval setting); compare the published retrieval methods if staining needs optimization (PMC11975906; PMC9818799).
Section 2
What Is the Expected TUBA1A Staining Pattern?
TUBA1A is a cytoplasmic microtubule protein with no transmembrane segment (UniProt Q71U36). In paraffin-section IHC, expect predominantly cytoplasmic staining in HPA-positive cells, including cortical and caudate neurons and several glandular cell populations (HPA: tissue IHC). HPA rates its tissue IHC reliability Enhanced, while reporting medium agreement with RNA data and warning that the staining may represent proteins from more than one gene (HPA: tissue IHC).
| Cytoplasmic staining in cortical or caudate neurons, with little staining in skeletal myocytes. | This fits the reported high neuronal staining and undetected myocyte staining (HPA: tissue IHC). Interpret the result by cell type and compartment; HPA cautions that its tissue pattern may include protein from more than one gene (HPA: tissue IHC). |
| Staining is predominantly nuclear or confined to cell membranes. | That distribution does not fit the reported cytoplasmic IHC profile or cytoskeletal localization (HPA: tissue IHC; UniProt Q71U36). Review morphology and controls before scoring it as target staining (general IHC practice). |
| Strong staining appears in skeletal myocytes while the section's expected positive cells stain weakly. | HPA reports TUBA1A staining as undetected in skeletal myocytes (HPA: tissue IHC). Consider cross-reactivity or endogenous detection activity; this pattern alone cannot identify which is responsible (general IHC practice). |
| Color spreads across tissue, stroma, and blank areas without a clear cell pattern. | Diffuse deposition is difficult to score as cytoplasmic staining (general IHC practice). Compare with a no-primary control to assess detection background, then review washing, blocking, and chromogen development (general IHC practice). |
| No signal appears in cortical neurons or another documented high-staining population. | The result conflicts with HPA's reported high staining in those cells (HPA: tissue IHC). Check a documented positive section and the detection run before concluding that the specimen lacks TUBA1A (general IHC practice). |
💡Expected TUBA1A appearanceCall a positive result when staining is predominantly cytoplasmic in an expected cell population and clearly above background, especially high-staining neurons or glandular cells (HPA: tissue IHC); isolated nuclear or membrane color is suspect (HPA: tissue IHC; UniProt Q71U36).
| Tissue and cell type | HPA reports high staining in cortical and caudate neurons, glandular cells at several listed sites, and marrow hematopoietic cells; heart cardiomyocytes are low and skeletal myocytes undetected (HPA: tissue IHC). |
| Attribution to TUBA1A | The tissue profile is rated Enhanced, but HPA notes medium staining–RNA consistency and possible detection of protein from more than one gene (HPA: tissue IHC). A positive slide therefore supports a pattern, not gene-specific identity. |
| Protein forms and epitope | UniProt lists two isoforms, a full-length chain, a detyrosinated chain, and modified residues (UniProt Q71U36). The supplied sources do not locate this antibody's epitope, so they do not establish which forms it detects. |
| Detection background | Endogenous enzyme activity can contribute color in chromogenic IHC; a no-primary control and an appropriate blocking step help assess it (general IHC practice). This is workflow guidance, not a reported TUBA1A-specific effect. |
| IF/ICC Q: What pattern should I expect? | A: HPA reports microtubules as the main location and the primary cilium as an additional location (HPA: subcellular ICC-IF). The separate IF/ICC guide covers its workflow. |
| Situation | Likely cause | Next action |
|---|---|---|
| A documented high-staining tissue shows no signal. | The run or primary-antibody detection may have failed; the slide alone cannot distinguish a technical failure from specimen variation (general IHC practice). | Check a concurrently processed positive section with reported high-staining cells, such as cortical neurons (HPA: tissue IHC), then review the IHC detection steps (general IHC practice). |
| Skeletal myocytes show strong color. | This conflicts with HPA's undetected skeletal-myocyte result and may reflect nonspecific binding or endogenous detection activity (HPA: tissue IHC; general IHC practice). | Compare a no-primary control and the expected positive cells on the run; reassess blocking and detection conditions if the control develops color (general IHC practice). |
| Staining is mainly nuclear or outlines membranes. | The distribution conflicts with the cytoplasmic IHC profile and cytoskeletal annotation (HPA: tissue IHC; UniProt Q71U36). | Confirm cell boundaries and counterstain, compare the no-primary control, and score only a reproducible compartment-consistent pattern (general IHC practice). |
| Most structures have diffuse brown background. | Nonspecific deposition or overdevelopment can obscure cell-level interpretation (general IHC practice). | Use a no-primary control to localize background; review washing, blocking, and chromogen development against the IHC workflow (general IHC practice). |
| A low-staining heart section seems negative. | HPA reports low staining in cardiomyocytes, so absence of a clear signal there is less informative than in a high-staining population (HPA: tissue IHC). | Assess a concurrently processed high-staining tissue before interpreting the heart result, and compare like cell types when scoring (HPA: tissue IHC; general IHC practice). |
| Strong cytoplasmic staining is taken as proof of TUBA1A alone. | HPA explicitly cautions that its tissue staining may detect protein from more than one gene (HPA: tissue IHC). | Report the observed cell pattern and antibody-based result without claiming gene-specific identity; use independent specificity evidence if that distinction is required (HPA: tissue IHC; general IHC practice). |
Experiment evidence
IHC & IF images showing TUBA1A staining
A03989 · IHCImmunohistochemistry of alpha-Tubulin in human brain tissue with alpha-Tubulin antibody at 2.5 μg/ml.
A03989 · IHCImmunohistochemistry of alpha-Tubulin in human brain tissue with alpha-Tubulin antibody at 5 μg/mL.
A03989 · IFImmunofluorescence of alpha-Tubulin in human brain tissue with alpha-Tubulin antibody at 20 μg/mL.
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000167552-TUBA1A/tissue/cerebral+cortex#imid_2576924
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000167552-TUBA1A/tissue/colon#imid_2576858
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000167552-TUBA1A/tissue/liver#imid_2576851
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000167552-TUBA1A/tissue/kidney#imid_2576852
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA039247; green = TUBA1A, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA039247; green = TUBA1A, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for TUBA1A IHC & IF
🧪Run adrenal gland first; its glandular cells should stain (HPA: High in adrenal gland glandular cells). Use skeletal muscle myocytes as the negative tissue (HPA: Not detected in skeletal muscle myocytes); no internal negative cell population is identified for the adrenal slide in the supplied HPA rows, so assess background in cells without specific staining.
Positive control tissue: Adrenal gland (Glandular cells, HPA High)
Negative control tissue: Skeletal muscle (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show TUBA1A in A-431, U-251MG, U2OS, PC-3, ASC52telo, RPTEC/TERT1, hTERT-RPE1 (serum starved), with annotated localisation: Microtubules (enhanced) (HPA subcellular).
Technical controls: Include no-primary (secondary-only) and host-species-, immunoglobulin-class-, and clonality-matched isotype controls, plus a TUBA1A knockout specimen as a biological specificity control (standard IHC practice). For chromogenic detection in adrenal tissue, check for endogenous peroxidase signal and quench it if present (standard IHC practice).
⚠️Feasibility: A target-specific fixation window and dependence on antigen retrieval are unreported in the supplied evidence; the selected A03989 tissue-IHC caption also leaves the fixative unreported (catalog caption: fixative not stated). HPA reports microtubule localisation in ICC-IF images, but the supplied evidence does not establish whether frozen sections or IF are easier than paraffin IHC (HPA: Microtubules enhanced). Assess adrenal background during optimisation; no adrenal-specific artefact is established by the supplied evidence.
HPA tissue IHC evidence for TUBA1A
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — Medium consistency between antibody staining and RNA expression data. Caution, targets protein from more than one gene.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | Glandular cells | High | Protein (IHC) | HPA → |
| Appendix | Glandular cells | High | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | High | Protein (IHC) | HPA → |
| Breast | Glandular cells | High | Protein (IHC) | HPA → |
| Bronchus | Basal cells | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Skeletal muscle | Myocytes | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced TUBA1A IHC Tips
Troubleshoot chromogenic TUBA1A staining in paraffin sections by checking retrieval, staining pattern, antibody specificity and cell-level controls.
What retrieval should I try first for weak TUBA1A staining in paraffin sections?
Start with citrate pH 6.0 heat-induced retrieval at 95–98 °C for 20 min (page retrieval setting). Compare a retrieved section with an otherwise matched section to judge whether retrieval improves cytoplasmic staining without increasing background (standard IHC practice; UniProt Q71U36: cytoskeleton). Let sections cool consistently, then keep antibody concentration and detection conditions matched so retrieval is the main variable (standard IHC practice). If staining remains weak, adjust retrieval duration in small increments while checking tissue integrity and nonspecific staining; a harsher condition can obscure whether a gain is specific (standard IHC practice).
Could fixation explain weak or uneven TUBA1A IHC staining?
Target-specific sensitivity to fixation is unknown from the supplied evidence; the A03989 human brain IHC caption does not state a fixative (A03989 caption). Record the fixative, fixation duration and processing history for each section before comparing staining across specimens (standard IHC practice). On matched sections, keep citrate pH 6.0 retrieval at 95–98 °C for 20 min constant while assessing whether staining varies with processing history (page retrieval setting; standard IHC practice). Examine morphology alongside staining, since poorly preserved tissue makes a cytoplasmic pattern difficult to score reliably (standard IHC practice; UniProt Q71U36: cytoskeleton).
Where should convincing TUBA1A staining appear in tissue?
Expect predominantly cytoplasmic staining associated with the cytoskeleton, rather than a nuclear pattern (UniProt Q71U36: subcellular location; HPA tissue IHC: general cytoplasmic expression). Microtubules are the enhanced main location in cell imaging, with additional supported primary-cilium localisation (HPA subcellular). In chromogenic sections, judge a fine cellular pattern against morphology; section thickness and chromogen deposition can limit resolution of individual microtubules (standard IHC practice). Use cerebral cortex neuronal cells as one documented high-staining reference, while recognising that high staining also occurs in several non-neuronal cell types (HPA tissue IHC: high in cerebral cortex neuronal cells and other listed cells).
Can this antibody distinguish TUBA1A isoforms or modified tubulin?
Do not assign staining to a particular TUBA1A isoform without epitope and cross-reactivity evidence: UniProt lists 2 isoforms (UniProt Q71U36: isoforms). The record also lists a detyrosinated chain ending at residue 450 and modifications including acetyllysine 40 and phosphoserine 439 (UniProt Q71U36: processing and modified residues). If the antibody epitope is unknown, staining alone cannot establish which of those forms it recognises (standard immunostaining interpretation). HPA cautions that its tissue staining may reflect protein from more than one gene, so verify isoform or gene specificity with appropriate orthogonal evidence before making that claim (HPA tissue IHC: reliability description).
How should I adapt the localisation check for TUBA1A IF?
For IF, pair TUBA1A with a separately labelled marker identifying the expected cell type, then assess overlap within individual cells rather than relying on tissue position alone (standard IF practice). Choose fluorophores after inspecting tissue autofluorescence in an unstained control, and place the signal of interest in a channel with useful contrast (standard IF practice). Because TUBA1A is cytoplasmic and cytoskeletal, use controlled permeabilisation when intracellular epitope access is needed, checking that morphology remains intact (UniProt Q71U36: subcellular location; standard IF practice). Compare the resulting pattern with microtubule and possible primary-cilium localisation, without treating the brain IHC caption as IF validation (HPA subcellular; A03989 caption).
How can I separate true cytoplasmic signal from chromogenic background?
First inspect a section processed without primary antibody to assess background from detection reagents and tissue (standard IHC practice). Include a peroxidase block before chromogenic detection and compare background after DAB development under matched conditions; these are general IHC workflow steps (standard IHC practice). If diffuse brown staining obscures cell boundaries, optimise blocking, washing, primary concentration and development time one variable at a time (standard IHC practice). Retain a positive reference with documented cytoplasmic staining, such as cerebral cortex neuronal cells, while remembering that HPA also reports high staining in other listed cell types (HPA tissue IHC: general cytoplasmic expression and positive cells).
What should I measure when comparing TUBA1A IHC across sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the tissue compartment and eligible cell type before scoring, then use a consistent percentage-positive or H-score approach across matched sections (standard IHC practice). An H-score can combine the percentage of cells at each staining intensity into a single cell-level summary, provided the intensity thresholds are fixed in advance (standard IHC practice). Normalise positive-cell counts to the number of eligible cells, or report positive-cell density per mm² of viable analysed tissue when cell counts are impractical (standard IHC practice). Record retrieval, detection and imaging conditions with each score because changes in these steps can alter measured chromogen intensity (standard IHC practice).
What findings would make a TUBA1A-positive result doubtful?
A convincing result follows cellular cytoplasm and plausible cytoskeletal distribution, with morphology that identifies the stained cells (UniProt Q71U36: subcellular location; HPA tissue IHC: general cytoplasmic expression). Isolated nuclear colour, staining restricted to section edges or necrotic areas, and signal persisting without primary antibody warrant an artefact check (standard IHC practice). Investigate endogenous peroxidase contribution with the appropriate detection controls before assigning brown deposits to TUBA1A (standard IHC practice). High neuronal-cell staining in cerebral cortex is compatible with the HPA pattern, but tissue distribution alone cannot establish gene-specific recognition because HPA cautions that staining may include protein from more than one gene (HPA tissue IHC: positive cells and reliability description).
Boster reagents
Best TUBA1A / Tubulin alpha-1A chain IHC Antibodies
The IHC-validated antibody A03989 has images of human brain tissue by IHC and IF (catalog image captions); its listed reactivity covers human, mouse, and rat (catalog reactivity).
Real IHC data
Anti-alpha-Tubulin TUBA1A Antibody
Cat # A03989
A03989 is the SKU with a rendered card and an IHC image of human brain tissue at 2.5 μg/mL (catalog image caption). Its IF image shows human brain tissue at 20 μg/mL, and its application list includes IHC-P and IF (catalog image caption; catalog applications).
Which to pick: For paraffin-section IHC, choose A03989 (catalog applications: IHC-P); its IHC caption shows human brain tissue but does not report the fixative (catalog image caption). For IF, choose A03989 (catalog applications: IF); ICC validation is unreported (catalog applications). For work requiring chicken reactivity, consider mouse monoclonal M03989-5, which lists chicken alongside human, mouse, and rat and an IHC paraffin-section dilution of 1–2 μg/mL (catalog host, clone, reactivity, and dilution); no IHC image caption or fixative is reported for that SKU (catalog image alts).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q71U36 (TBA1A_HUMAN, Tubulin alpha-1A chain).
- Human Protein Atlas. TUBA1A tissue IHC expression (reliability: Enhanced).
- Human Protein Atlas. TUBA1A subcellular location (ICC-IF): Mainly localized to the microtubules. In addition localized to the primary cilium..
- Human Protein Atlas. TUBA1A antibody validation summary (4 antibodies).
- Single-cell sequencing reveals the role of aggrephagy-related patterns in tumor microenvironment, prognosis and immunotherapy in endometrial cancer. Frontiers in oncology 2025 — PMC11975906.
- Genes Related to Motility in an Ionizing Radiation and Estrogen Breast Cancer Model. Biology 2024 — PMC11591951.
- Arf-like Protein 2 (ARL2) Controls Microtubule Neogenesis during Early Postnatal Photoreceptor Development. Cells 2022 — PMC9818799.
- Single-cell landscape analysis reveals distinct regression trajectories and novel prognostic biomarkers in primary neuroblastoma. Genes & diseases 2022 — PMC9485279.
- PubMed PMID:3839072 — UniProt-cited evidence.
- PubMed PMID:11504633 — UniProt-cited evidence.
- PubMed PMID:14702039 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for TUBA1A (Tubulin alpha-1A chain). Expected localisation General cytoplasmic tissue staining (HPA tissue IHC). Antigen retrieval: Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen). Validated IHC antibody: A03989 at 2.5 μg/mL (the product's own IHC validation image is shown). Controls (HPA): positive Adrenal gland (Glandular cells); negative Skeletal muscle. IHC workflow; specimen preparation unspecified. Protocol steps: 1. Sample: Tissue sections; selected-image fixative not specified (standard IHC workflow); 2. Fixation: Image fixative and duration unreported (datasheet A03989); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat-induced epitope retrieval in citrate buffer, pH 6.0 , 20 min at 95–98 °C…; 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit anti-TUBA1A, 2.5 μg/mL (datasheet A03989); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Keep fixation consistent across paraffin sections (standard IHC practice; not target-specific); Caveat: Staining may reflect protein from more than one gene (HPA tissue IHC); Isoform / epitope: 2 isoforms; terminal processing may alter epitopes (UniProt); Regulation: High expression in fetal brain (UniProt). Evidence: UniProt Q71U36, HPA tissue IHC · Enhanced, HPA ICC-IF · Mainly localized to the microtubules. In addition localized to the…, Datasheet A03989, PMC11975906, PMC9818799. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/TUBA1A/immunohistochemistry-ihc-guide.